Company Profile
Medigen Biotechnology Corp., a biopharmaceutical company provides the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan.
It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan.
Its portfolio also includes is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan, and in phase II study in combination with ICI for head and neck cancer, and gastric cancer patients in the United States. Founded in 1990, Medigen Biotechnology is headquartered in Taipei, Taiwan.